• After a single dose of anti-PD-1, rapid pathologic and clinical responses associated with accumulation of exhausted CD8+ T cells in the tumor at 3 weeks, with reinvigoration in the blood observed as early as 1 week; • A pre-treatment immune signature (neoadjuvant response signature) associated with clinical benefit. The gene discussed is CD8A; the disease is neoplasm.